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ABSTRACT 
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Purpose: To investigate whether chronic supplementation with a low or moderate dose of 
dietary nitrate (NO3-) reduces submaximal exercise oxygen uptake ( O2) and to assess whether 
or not this is dependent on acute NO3- administration prior to exercise. Methods: Following 
baseline tests, 34 healthy subjects were allocated to receive 3 mmol NO3-, 6 mmol NO3- or 
placebo. Two hours following the first ingestion, and after 7, 28 and 30 days of 
supplementation, subjects completed two moderate-intensity step exercise tests. On days 28 
and 30, subjects in the NO3- groups completed the test 2 h post consumption of a NO3- dose 
(CHR+ACU) and a placebo dose (CHR). Results: Plasma nitrite concentration ([NO2-]) was 
elevated in a dose-dependent manner at 2 h, 7 days and 28-30 days on the CHR+ACU visit. 
Compared to pre-treatment baseline, 6 mmol NO3- reduced the steady-state O2 during 
moderate-intensity exercise by 3% at 2 h (P = 0.06), 7 days and at 28-30 days (both P < 0.05) 
on the CHR+ACU visit, but was unaffected by 3 mmol NO3- at all measurement points. On the 
CHR visit in the 6 mmol group, plasma [NO2-] had returned to pre-treatment baseline, but the 
steady-state O2 remained reduced.  Conclusion: Up to ~4 weeks supplementation with 6 but 
not 3 mmol NO3- can reduce submaximal exercise O2. A comparable reduction in submaximal 
exercise O2 following chronic supplementation with 6 mmol NO3- can be achieved both with 
and without the acute ingestion of NO3- and associated elevation of plasma [NO2-].  
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Abbreviations: ANOVA, analysis of variance; ATP, adenosine triphosphate; CHR, effect of 
chronic nitrate supplementation alone assessed; CHR + ACU, combined effect of chronic and 
acute nitrate supplementation assessed; GET, gas exchange threshold; NO, nitric oxide; NO2-, 
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nitrite; NO3-, nitrate; O2, oxygen; PLA, placebo; Rpm, revolutions per minute; O2, oxygen 
uptake; O2peak, peak oxygen uptake; W, watts; ∆, change. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
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Dietary nitrate (NO3-) has been reported to influence several physiological processes via its 
reduction to nitrite (NO2-), and subsequently to the physiological signaling molecule nitric 
oxide (NO) [1–3]. Indeed, acute ingestion (1-3 h) and chronic supplementation (3-15 days) 
with dietary NO3- has been found to increase plasma NO2- concentration [NO2-], and, in some 
studies, to reduce the oxygen (O2) cost of submaximal exercise [4–6] and improve exercise 
tolerance [5–7] in healthy, young adults (see [8] for review). However, the influence of 
different supplementation strategies on the physiological effects of NO3- ingestion is still not 
fully understood.  
 
Whilst a reduction in the O2 cost of submaximal exercise has been reported 1-3 h post 
consumption of 5.2-16.8 mmol NO3- in some studies [6,9,10], reports on the effect of ingesting 
a lower dose (i.e. 4.2 mmol NO3- or below) are ambiguous [6,11]. It has been suggested that 
chronic supplementation with NO3- may represent a more effective supplementation strategy 
[8,10]. Indeed, 3-7 days of NO3- supplementation has been reported to improve mitochondrial 
efficiency [12] and contractile function [13] by altering the expression of mitochondrial [12] 
and contractile [13] proteins in skeletal muscle. These structural adaptations are likely to be 
responsible, in part, for the reduction in submaximal O2 uptake ( O2) after chronic NO3- 
supplementation, but would unlikely be manifest within 1-3 h after the ingestion of a single 
NO3- bolus. Given this potential benefit of a chronic NO3- supplementation period, it may be 
reasoned that a significant and consistent reduction in submaximal exercise O2 could be 
achieved with a low dose of NO3- if consumed daily for an extended period of time. However, 
the effect of chronic supplementation with a low dose of NO3- (i.e. 4.2 mmol or lower) on the 
O2 cost of submaximal exercise has not yet been investigated. Every nutritional supplement 
has an associated risk-benefit relationship and financial cost. Determining if a low dose of NO3- 
consumed chronically can elicit beneficial physiological effects is therefore important to guide 
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supplementation procedures and ensure individuals do not consume more NO3- than is 
required.  
 
To fully understand the physiological effects of a chronic and acute supplementation strategy, 
it is important to examine the effects of each strategy independently. In all previous studies 
assessing the influence of chronic NO3- supplementation on the physiological responses to 
exercise, subjects have been instructed to consume their final dose of NO3- 1-3 hours prior to 
final exercise testing, to ensure a significant elevation in plasma [NO2-] [e.g. 4,5,7,9]. However, 
this experimental design only allows for the combined chronic and acute effect of NO3- 
ingestion to be investigated. Indeed, it is possible that: a) any chronic adaptions to daily NO3- 
intake would be detectable in the absence of an acute NO3- dose and thus, no significant 
elevation in plasma [NO2-]; and b) any chronic effects of NO3- supplementation may be 
augmented if an acute NO3- dose is consumed. The adoption of an experimental approach in 
which the chronic effects of NO3- exposure can be isolated from those of the acute effects is 
therefore warranted. This will provide important practical information to guide athletes on 
optimal supplementation strategies before competition after a period of chronic NO3- 
supplementation.  
 
The purpose of this study was therefore twofold: firstly, to compare the effects of acute (2 h), 
7 d and ~30 d supplementation, with a low dose (3 mmol) and a moderate dose (6 mmol; 
positive control) of dietary NO3- on the O2 cost of moderate-intensity exercise; and, secondly, 
to compare the effect of ~30 day supplementation on the O2 cost of moderate-intensity exercise 
with and without the acute consumption of NO3- 2 h prior to assessment. To achieve the latter, 
subjects completed an experimental visit on day 28 and 30 of supplementation: on one visit 
subjects consumed an acute dose of NO3- 2 h prior to testing (CHR + ACU); and on the other 
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visit, exercise was initiated 24 h post consumption of the most recent NO3- dose (CHR), 
allowing plasma [NO2-] to return to pre-NO3- treatment baseline [6]. It was hypothesized that: 
a) supplementation with 3 mmol NO3- and 6 mmol NO3- would result in a lower O2 cost of 
submaximal exercise at 7 d and 28-30 d on the CHR + ACU visit; and, b) any effects observed 
with CHR + ACU would still be present, albeit to a lesser extent, with CHR.   
 
2. METHODS 
2.1. Subjects 
Thirty-four healthy, recreationally-active subjects (19 male, mean ± SD age = 21 ± 3 yr, stature 
= 1.74 ± 0.09 m, body mass = 73.5 ± 14.1 kg) volunteered to participate, gave written informed 
consent, and completed this study that was approved by the Institutional Research Ethics 
Committee. All subjects were nonsmokers and none were taking any nutritional supplements 
in the four months preceding the start of the study. Throughout the experimentation, subjects 
were asked to adhere to their normal exercise routine and diet. However, subjects were 
instructed to avoid foods rich in NO3- (such as green leafy vegetables and beetroot) and asked 
to record their diet and exercise in the 48 h preceding the first laboratory visit and to repeat this 
prior to all subsequent visits. Subjects were instructed to arrive at the laboratory in a rested and 
fully hydrated state, at least 2 h postprandial, and to avoid strenuous exercise in the 24 h 
preceding each testing session. Each subject was also asked to avoid caffeine and alcohol 6 and 
24 h before each test, respectively. In addition, subjects were asked to abstain from using 
antibacterial mouthwash and chewing gum for the duration of the study since this inhibits the 
reduction of NO3- to NO2- in the oral cavity [14]. All laboratory visits were scheduled at the 
same time of day (± 1 h) for each subject. 
 
2.2. Pre-treatment tests 
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Subjects were required to report to the laboratory on two separate occasions prior to beginning 
30 days of supplementation with 3 mmol NO3-, 6 mmol NO3-, or placebo (PLA). All exercise 
tests were performed on an electronically-braked cycle ergometer (Lode Excalibur Sport, 
Groningen, The Netherlands). During visit 1, subjects completed a ramp incremental exercise 
test to the limit of tolerance for the determination of peak O2 ( O2peak) and gas exchange 
threshold (GET). The subjects cycled at a constant self-selected pedal rate (80-90 rpm), and 
this pedal rate, along with saddle and handle bar height configuration, was recorded and 
reproduced in subsequent tests. Initially, subjects performed 3 min of baseline cycling at 20 W, 
after which the work rate increased at a rate of 30 W·min-1 in a linear fashion until the limit of 
tolerance. The test was terminated when the pedal rate fell by > 10 rpm below the chosen pedal 
rate, despite strong verbal encouragement. The power output achieved at the point of 
exhaustion was recorded as the peak power output (PPO). Pulmonary gas exchange was 
continuously collected breath-by-breath during the incremental tests and averaged over 
consecutive 10-s periods. The O2peak was calculated as the highest 30-s mean value attained 
before the subject’s volitional exhaustion.  The GET was determined as described previously 
[15,16]. The work rate that would require 80 % of the GET (moderate exercise) was then 
calculated, with account taken of the mean response time for O2 during ramp exercise (i.e. 
two-thirds of the ramp rate was deducted from the work rate at GET; [17]).  
 
During visit 2, subjects completed a series of PLA-controlled, baseline measurements. All 
subjects were asked to consume a 50 mL dose of PLA containing negligible NO3- (see 
description under Supplementation procedures for further details), 2 h prior to arrival at the 
laboratory. Upon arrival a venous blood sample was obtained for the measurement of plasma 
[NO3-] and [NO2-]. Subjects then completed two step transitions to moderate-intensity cycling 
at 80 % GET, with each bout separated by 5-min of passive recovery. Each step transition was 
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preceded by 3-min of baseline cycling at 20 W and each bout lasted 5 min. Pulmonary O2 was 
measured breath-by-breath throughout the test and averaged over 10-s periods. The data from 
the two moderate-intensity bouts were time aligned and averaged to improve signal-to-noise 
ratio [18]. The O2 cost of moderate-intensity exercise was then calculated. All measurements 
made during this visit were used as pre-treatment baseline data.  
 
2.3. Supplementation procedures 
After these pre-treatment visits, subjects were assigned in a group-matched fashion for 
moderate-intensity end-exercise O2, PPO, GET and O2peak, to receive either ~3 mmol NO3- 
(administered as 9.75 g of dry beetroot extract [PepsiCo, USA] diluted in 50 mL of water), ~6 
mmol NO3- (administered as 19.5 g of dry beetroot extract [PepsiCo, USA] diluted in 50 mL 
of water), or a PLA (containing ~0.01 mmol of NO3-, administered as 9.5 g of sucrose and red 
shade coloring [PepsiCo, USA] diluted in 50 mL of water) per day, for 30 days. Subject 
characteristics are provided in Table 1.  
 
Subjects reported to the laboratory on days 1, 7, 28 and 30 of supplementation to complete the 
full experimental protocol from visit 2 (Fig. 1). On supplementation days 1 and 7, subjects were 
asked to consume their 1st and 7th dose of supplement, respectively, 2 h prior to arrival at the 
laboratory. This pre-test consumption time was selected in order to coincide with the peak 
plasma [NO2-]. While we have previously established that peak plasma [NO2-] is attained 2 h 
post beetroot juice consumption [6], it could not be assumed that this time-to-peak is consistent 
after consumption of other NO3- containing supplements because the kinetics of plasma [NO2-] 
may be altered by the form in which the NO3- is administered [19]. We therefore undertook a 
pilot study which indicated that peak plasma [NO2-] occurred at 2 h post consumption of the 
dry beetroot extract (unpublished observation).  On non-experimental days, each subject was 
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instructed to consume their allocated supplement at their test time from visit 2 (± 10 min), such 
that the subject would consume one dose of supplement every 24 h.  
 
To assess the effect of chronic NO3- supplementation on the O2 cost of submaximal exercise 
with and without the acute consumption of NO3- 2 h prior to exercise, a randomised counter-
balanced design was adopted from day 28 of supplementation for subjects in the 3 mmol and 
6 mmol groups (Fig. 1). Two hours prior to arrival on day 28 of supplementation, subjects in 
the 3 mmol and 6 mmol groups were asked to consume either a PLA beverage [i.e. effect of 
chronic NO3- supplementation alone (CHR) was assessed] (3 mmol: n = 6; 6 mmol: n = 6) or 
their allocated NO3--rich beverage [i.e. combined effect of chronic and acute NO3- 
supplementation (CHR + ACU) was assessed] (3 mmol: n = 5; 6 mmol: n = 6). Ten-minutes 
post completion of the test procedures on day 28, subjects in the 3 mmol and 6 mmol group 
who consumed PLA prior to the test, consumed a dose of their allocated NO3--rich beverage, 
and those that consumed their NO3--rich beverage consumed a PLA beverage. Two hours prior 
to arrival at the laboratory on day 30, subjects consumed the opposite beverage to that 
consumed prior to their laboratory visit on day 28 [e.g. if PLA was consumed prior to arrival 
on day 28, then their allocated NO3--rich beverage was consumed prior to arrival on day 30]. 
Therefore, all subjects were assessed for the CHR + ACU and CHR effects of NO3- 
supplementation.  In all cases, subjects in the 3 mmol and 6 mmol groups consumed 3 mmol 
NO3- or 6 mmol NO3-, respectively, per day. Subjects in the PLA group were instructed to 
continue their normal supplementation routine and consume one dose of PLA 2 h prior to 
arrival at the laboratory on both day 28 and 30 of supplementation. 
Subjects in the 3 mmol and 6 mmol groups were deliberately misinformed that the effects of 
two different NO3- supplements on the physiological responses of exercise would be tested 
after different supplementation periods.  Subjects in the PLA group were informed that the 
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effect of a NO3- supplement would be tested over different supplementation periods. All 
subjects were asked to not comment on the taste or appearance of the supplements to the study 
investigators. Follow up verbal interviews after completion of the study confirmed that subjects 
were unaware of the actual research hypothesis.  
  
2.4. Measurements and data analysis 
During all exercise tests, pulmonary gas exchange and ventilation were measured breath-by-
breath, with subjects wearing a nose clip and breathing through a low dead space, low-
resistance mouthpiece and impeller turbine assembly (Jaeger Triple V, Hoechberg, Germany). 
The inspired and expired gas volume and gas concentration signals were continuously sampled 
at 100 Hz, the latter using paramagnetic (O2) and infrared (CO2) analyzers (Jaeger Oxycon Pro, 
Hoechberg, Germany) via a capillary line connected to the mouthpiece. The gas analyzers were 
calibrated before each test with gases of known concentration, and the turbine volume 
transducer was calibrated with a 3-liter syringe (Hans Rudolph, Kansas City, MO). Pulmonary 
gas exchange and ventilation were calculated and displayed breath-by-breath.  
 
The breath-by-breath gas exchange data collected during the two identical, moderate-intensity 
step tests performed at pre-treatment baseline on visit 2 and on days 1, 7, 28 and 30 of 
supplementation, were averaged over 10-s periods, and time aligned to the start of exercise and 
ensemble-averaged. The end-exercise O2 was defined as the mean value measured over the 
final 60 s of exercise.  
 
Venous blood samples were drawn into lithium-heparin vacutainers (7.5 ml Monovette lithium 
heparin; Sarstedt, Leicester, UK). Within 1 min of collection, samples were centrifuged at 
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4,000 rpm and 4 °C for 8 min. Plasma was extracted and immediately frozen at -80 °C for later 
analysis of [NO3-] and [NO2-] as previously described [6]. 
 
Capillary blood samples were collected from a fingertip into a capillary tube during the 20 s 
preceding each step transition in work rate and within the final 20 s of each moderate-intensity 
bout. These samples were subsequently stored on ice and analyzed to determine blood [lactate] 
(YSI 1500, Yellow Springs Instruments, Yellow Springs, OH), within 5 min of collection.   
 
2.5. Statistical analysis 
A mixed-model ANOVA was used to assess differences in change from pre-treatment baseline, 
in all variables across treatment (PLA, 3 mmol NO3- and 6 mmol NO3-) and time (2 h and 7 d, 
and the CHR + ACU visit on day 28 or 30 of supplementation). Differences over time within 
each group were analyzed by a single factor repeated-measures ANOVA. Before these 
analyses, all data collected on days 28 and 30 of supplementation in the PLA group were 
averaged together to form one data point at days 28 and 30 of supplementation. The effect of 
CHR on all variables in 3 mmol and 6 mmol was analyzed separately using a single factor 
repeated measures (pre-treatment baseline, CHR and CHR + ACU) ANOVA. In all cases, 
significant effects were further explored using simple contrasts. All data analyses were 
performed using the SPSS (version 22; SPSS, Chicago, IL) statistical package, with statistical 
significance accepted at P<0.05. Results are presented as mean ± SD unless stated otherwise.  
 
3. RESULTS 
Self-reported compliance to the supplementation regime was 100 % in all treatment groups. 
Subjects reported that their diet and exercise habits prior to each experimental test were 
consistent.  
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3.1. Plasma [NO3-] and [NO2-] 
Plasma [NO3-] and [NO2-] responses in PLA, 3 mmol and 6 mmol groups are presented in 
Figures 2 and 3.  
 
3.1.1. 2 h, 7 d and 28-30 day (CHR + ACU) 
At pre-treatment baseline, plasma [NO3-] was not significantly different between treatment 
groups (PLA: 33 ± 11 µM; 3 mmol: 46 ± 24 µM; 6 mmol: 36 ± 11 µM: P > 0.05).  The change 
in plasma [NO3-] from pre-treatment baseline at 2 h, 7 d and on the CHR + ACU visit after 28-
30 d is shown in Fig. 2A. Plasma [NO3-] was significantly elevated above pre-treatment 
baseline and PLA at all time points in the 3 mmol and 6 mmol groups (all P < 0.05; Fig. 2A). 
The elevation in plasma [NO3-] above pre-treatment baseline in the 6 mmol group was greater 
than in the 3 mmol group at all time points (all P < 0.05; Fig. 2A). The mean increase in plasma 
[NO3-] from pre-treatment baseline, in the 3 mmol and 6 mmol groups across the three sample 
points was 313% and 867%, respectively (3 mmol: 144 ± 23 µM; 6 mmol: 312 ± 68 µM; both 
P < 0.05; Fig. 2A). No changes in plasma [NO3-] were observed in the PLA group at any time 
point (all P > 0.05). The rise in plasma [NO3-] from pre-treatment baseline was not significantly 
different between the three sampling time points within any treatment group (all P > 0.05).   
 
At pre-treatment baseline, plasma [NO2-] was not significantly different between treatment 
groups (PLA: 43 ± 19 nM; 3 mmol: 80 ± 69 nM; 6 mmol: 48 ± 22 nM: P > 0.05). The change 
in plasma [NO2-] from pre-treatment baseline at 2 h, 7 d and on the CHR + ACU after 28-30 d 
is shown in Fig. 2B. In the 3 mmol and 6 mmol groups, plasma [NO2-] was significantly 
elevated at all time points (all P < 0.05; Fig. 2B), relative to pre-treatment baseline and PLA. 
In addition, the rise in plasma [NO2-] was greater in the 6 mmol group than in the 3 mmol group 
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at all time points (all P < 0.05; Fig. 2B). Across the three sample points, plasma [NO2-] rose by 
165% and 579%, above pre-treatment baseline, in the 3 mmol (132 ± 49 nM) and 6 mmol (278 
± 155 nM; all P < 0.05; Fig. 2B) groups, respectively. No changes in plasma [NO2-] were 
observed in the PLA group at any time point (all P > 0.05). The rise in plasma [NO2-] from 
pre-treatment baseline was not significantly different between the three sampling time points 
within any treatment group (all P > 0.05).   
 
3.1.2. Comparison between chronic and chronic + acute supplementation 
The change in plasma [NO3-] from pre-treatment baseline was significantly lower on the CHR 
visit compared to the CHR + ACU visit in both the 3 mmol and 6 mmol groups (P < 0.05; Fig. 
3A). In the 3 mmol group, plasma [NO3-] had returned to pre-treatment baseline on the CHR 
visit (P > 0.05; Fig. 3A). In the 6 mmol group, the plasma [NO3-] remained elevated above pre-
treatment baseline by 34 ± 36 µM (P < 0.05; Fig. 3A) on the CHR visit.   
 
The change in plasma [NO2-] from pre-treatment baseline was significantly lower on the CHR 
visit compared to CHR + ACU visit in the 3 mmol and 6 mmol groups (P < 0.05; Fig. 3B). 
Plasma [NO2-] had returned to pre-treatment baseline on the CHR visit in both the 3 mmol and 
6 mmol groups (P > 0.05; Fig. 3B) 
 
3.2. Moderate-Intensity Exercise 
At pre-treatment baseline, the O2 measured over the final 60-s of moderate intensity exercise 
was not significantly different between treatment groups (PLA: 1.46 ± 0.32 L·min-1; 3 mmol: 
1.44 ± 0.23 L·min-1; 6 mmol: 1.44 ± 0.30 L·min-1: P > 0.05).  
 
3.2.1. 2 h, 7 d and 28-30 day (CHR + ACU) 
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The change in end-exercise O2 from pre-treatment baseline at 2 h, 7 d and on the CHR + ACU 
visit after 28-30 d is shown in Fig. 4A. In the 3 mmol and PLA groups, end-exercise O2 was 
not significantly different from pre-treatment baseline at any time point (all P > 0.05; Fig. 4A). 
Compared to pre-treatment baseline, end-exercise O2 was significantly reduced in the 6 mmol 
NO3- group at 7 d (by ~3%; 0.04 ± 0.05 L·min-1) and 28-30 d on the CHR + ACU visit (by 
~3%; 0.04 ± 0.04 L·min-1; both P < 0.05; Fig. 4A), and tended to be reduced at 2 h (by ~3%; 
0.04 ± 0.02 L·min-1; P = 0.06; Fig. 4A). Compared to PLA, end-exercise O2 was significantly 
reduced in the 6 mmol group at 28-30 d on the CHR + ACU visit (P < 0.05; Fig. 4A) and 
tended to be reduced at 7 d (P = 0.08; Fig. 4A). Compared to pre-treatment baseline and PLA, 
baseline, end-exercise and change in blood [lactate] were not altered by 3 mmol or 6 mmol 
NO3- at 2 h, 7 d or 28-30 d on the CHR + ACU visit (P > 0.05).  
 
3.2.2. Comparison between chronic and chronic + acute supplementation 
In the 3 mmol group, end-exercise O2 was not different from pre-treatment baseline at 28-30 
d on either the CHR or CHR + ACU visits (P > 0.05). In the 6 mmol group, end-exercise O2 
was significantly lower than pre-treatment baseline at 28-30 days on the CHR visit (by ~3.5%; 
0.05 ± 0.06 L·min-1; P < 0.05; Fig. 4B). This reduction in end-exercise O2 was not 
significantly different from that observed on the CHR + ACU visit (P > 0.05; Fig. 4B).  
 
4. DISCUSSION 
The principal novel finding of the present study was that neither 7 days nor ~4 weeks of 
supplementation with 3 mmol NO3-, per day, reduced the O2 cost of moderate-intensity cycle 
exercise, despite an increase in plasma [NO3-] and [NO2-] throughout the supplementation 
period. In contrast, the greater rise in plasma [NO3-] and [NO2-] with 6 mmol NO3- was 
associated with a significant reduction in the O2 cost of moderate-intensity cycle exercise after 
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7 days and ~4 weeks of supplementation, and a trend (P = 0.06) for a reduction after acute (2 
h) ingestion. Interestingly, this reduction in moderate-intensity O2 after ~4 weeks of 
supplementation was still evident when assessed on a separate occasion without the ingestion 
of NO3- 2 h prior to the exercise test and thus, no elevation in plasma [NO2-]. This study is the 
first to demonstrate a lowering of submaximal O2 following chronic NO3- supplementation 
without a significant concomitant increase in systemic [NO2-].  
 
4.1. The influence of 2 h, 7 d and 28-30 d (Chronic + Acute) NO3- supplementation  
4.1.1. Plasma [NO3-] and [NO2-] 
The administration of beetroot extract containing 3 mmol and 6 mmol NO3- was successful in 
dose-dependently elevating plasma [NO3-] and [NO2-], a finding consistent with that observed 
after the ingestion of concentrated NO3--rich beetroot juice [6] and pharmaceutical NO3- salt 
[20]. In both the 3 mmol and 6 mmol groups, there was no further increase in plasma [NO3-] 
or [NO2-] after 7 days or 28-30 days supplementation (when an acute bolus of NO3- was 
consumed 2 h prior to assessment), compared to the acute ingestion of a single bolus of NO3- 
on day 1. This finding is also in line with previous observations [9,21].  
 
 
 
4.1.2. O2 cost of submaximal exercise  
In the present study we found that the steady-state O2 measured over the final 60 s of 
moderate-intensity cycle exercise was unaffected by the acute ingestion of 3 mmol NO3- but 
tended (P = 0.06) to be lower by 3% following acute ingestion of 6 mmol NO3-. Several 
previous studies have also reported a dose-response relationship, with higher but not lower 
doses of dietary NO3- eliciting physiological effects [6,22,23]. In particular, we have previously 
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reported that the O2 cost of submaximal cycling was unaffected by the acute administration of 
4.2 mmol NO3-, tended to be reduced (by 1.7%) following administration of 8.4 mmol NO3-, 
and was significantly reduced (by 3%) following administration of 16.8 mmol NO3-, 
administered in the form of concentrated beetroot juice [6]. The reason for the greater relative 
reduction in submaximal exercise O2  for a given NO3- dose in the present study (i.e. 3% 
reduction with 6 mmol NO3-) compared to that reported by us previously (i.e. 1.7% reduction 
with 8.4 mmol NO3-) [6] is unclear. However, despite this, the results presented herein and by 
us previously [6] support a dose-dependent effect of acute NO3- ingestion on submaximal 
exercise O2, and suggest that higher doses of NO3- (≥ 6 mmol NO3-) are required to acutely 
lower the O2 cost of submaximal exercise.   
 
This is the first study to investigate the effect of chronic supplementation with a low dose of 
NO3- on the O2 cost of moderate-intensity exercise. Contrary to our experimental hypothesis, 
we found that prolonging the supplementation period with 3 mmol NO3- to 7 days, and further 
to ~4 weeks, did not lower the O2 cost of submaximal cycle exercise. These results suggest that 
a reduction in submaximal exercise O2 cannot be achieved with a low dose of NO3- even with 
an extension of the supplementation period. In contrast, we found that the O2 cost of 
submaximal exercise was significantly lower than pre-treatment baseline after both 7 days and 
~4 weeks of supplementation with 6 mmol NO3-. These findings are in agreement with the 3-
6% reduction in the O2 cost of submaximal exercise reported in untrained subjects following 
3-15 days of supplementation with 5-8 mmol NO3- [4,5,9,12,24]. Therefore, these results 
indicate that the daily ingestion of 6 mmol NO3- reduces the O2 cost of submaximal exercise 
after short duration (7 day) supplementation, and that this effect is maintained over ~4 weeks 
of continued supplementation with no evidence of a reduced sensitivity to supplementation.  
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The lowering of submaximal exercise O2 may be a result of improved mitochondrial 
efficiency [12,25, cf. 26] and/or a reduction in the ATP cost of skeletal muscle force production 
[27]. Alterations in the expression, and therefore content, of mitochondrial [12] and contractile 
proteins [13] have been proposed as the mechanistic bases for these effects. However, 
alterations in protein expression are unlikely to occur within 1-3 h of acute NO3- ingestion, and 
can therefore only contribute to a reduction in submaximal exercise O2 after a period of 
chronic NO3- supplementation. Instead, a reduction in O2 following acute NO3- ingestion may 
be related to an acute and reversible change in protein function through post-translational 
protein modifications [28]. Given the potential for the protein expression changes to occur after 
chronic supplementation but not acute ingestion, we hypothesized that the prolonged exposure 
to elevated concentrations of NO2- provided by a chronic supplementation regime may reduce 
the dose of NO3- required to lower submaximal exercise O2. In contrast to this hypothesis we 
found that extending the duration of supplementation on a low dose of NO3- to ~4 weeks did 
not result in a reduction in submaximal exercise O2. This observation implies that these 
structural modifications are not only dependent on the duration of exposure but also the 
magnitude of the exposure. The influence of different NO3- doses and durations of 
supplementation on structural modifications to skeletal muscle warrants further investigation.     
 
4.2. The effect of chronic NO3- supplementation in the absence of acute NO3- ingestion 
 
In all previous studies examining the effect of chronic NO3- supplementation on the 
physiological responses to exercise, subjects have been instructed to consume their final dose 
of NO3- 1–3 h prior to testing [e.g. 4,5,9,12,27,29]. This experimental approach has been 
adopted to ensure a significant elevation in plasma [NO2-] (and therefore the potential for O2-
independent NO synthesis) at the time of assessment. However, considering that: 1) for a given 
dose, the rise in plasma [NO2-] afforded by this chronic supplementation strategy is not 
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different to that afforded by a single acute bolus of NO3- [9,21]; 2) acute NO3- supplementation 
may reduce submaximal exercise O2 and improve exercise tolerance [6]; and 3) the acute 
effects of NO3- are believed to be mediated via an elevation in plasma [NO2-] [6,9]; it is not 
possible to fully ascertain if the effects observed after chronic NO3- supplementation would 
still be evident when an acute NO3- dose is not administered.  Therefore, in the present study, 
we examined the effects of chronic NO3- supplementation both with and without administration 
of an acute NO3- dose. Specifically, subjects were asked to consume their final dose of NO3- 
24 h prior to exercise testing. Importantly, 24 h provided sufficient time for plasma [NO2-] to 
return to pre-treatment baseline, a finding that is in agreement with the pharmacokinetics of 
plasma [NO2-] following acute ingestion of similar NO3- doses [6,20].  
 
An original finding of the present study was that moderate-intensity steady-state O2 was 
significantly lowered following ~4 weeks of supplementation with 6 mmol NO3-, even when 
24 h had elapsed since the ingestion of the last NO3- dose. To our knowledge, these results are 
the first to demonstrate a reduction in submaximal exercise O2 following NO3- 
supplementation in the absence of an increase in plasma [NO2-]. However, this observation is 
consistent with a previous report that the physiological effects of NO3- supplementation can be 
achieved without an accompanying rise in plasma [NO2-] [30]. Specifically, Ferguson et al., 
[30] showed that despite no increase in plasma [NO2-] after 5 days of NO3- supplementation in 
rats, microvascular O2 partial pressure was elevated during contraction in fast-twitch skeletal 
muscle. Interestingly, the magnitude of reduction in O2 was not significantly different to that 
observed after ~4 weeks of supplementation when an acute bolus of NO3- was consumed prior 
to testing. These results therefore suggest that following chronic supplementation with 6 mmol 
NO3-, a reduction in the O2 cost of submaximal exercise may be preserved up to at least 24 h 
after the final dose of NO3- is ingested, and that the addition of an acute NO3- dose, and the 
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resulting elevation in plasma [NO2-], does not augment the reduction in submaximal exercise 
O2.  The mechanistic basis for this preserved reduction in O2 is currently unclear. However, 
as briefly discussed earlier, the reduction in submaximal O2 following chronic NO3- 
supplementation may be mediated, in part, by a change in the content of mitochondrial [12, cf 
26] and contractile [13]  proteins, and an associated improvement in mitochondrial [12, cf. 26] 
and contractile [13,27] efficiency. It is likely that such structural adaptations are maintained 
for some period of time after NO3- supplementation is stopped, resulting in the preserved 
reduction in steady-state O2. Indeed, the increased expression of mitochondrial proteins 
following sprint interval training have been observed up to 6 weeks after training was ceased 
[31].  
 
Another possible explanation for the preserved reduction in steady-state O2 is that other 
reactive nitrogen intermediates and/or NO bioavailability remained elevated post NO3- 
supplementation, despite plasma [NO2-] returning to pre-treatment baseline. Previous research 
in rodents has shown that skeletal muscle tissue acts as an endogenous NO2- and NO3- reservoir 
[32] and that NO2- infusion increases the concentration of NO2- in heart, liver and kidney tissue 
[33]. If this uptake is also true for human skeletal muscle following NO3- supplementation, it 
is possible that the pharmacokinetics of these changes are different to that of plasma [NO2-] 
and [NO3-], and as a result, tissue NO2- may accumulate and remain elevated beyond 24 h after 
the cessation of NO3- supplementation. An increase in tissue NO bioavailability may contribute 
to the reduction in O2 via acutely and reversibly impacting mitochondrial and/or contractile 
protein function through post-translational protein modifications [28]. The preserved lowering 
of O2 in the present study may therefore reflect a structural adaptation and/or elevated NO 
bioavailability in skeletal muscle tissue following ~4 weeks of supplementation with 6 mmol 
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NO3-. Further research is required to determine how long the reduction in submaximal exercise 
O2 may be preserved following cessation of NO3- supplementation.  
 
It should be noted that although the acute elevation of plasma [NO2-] following chronic NO3- 
supplementation did not augment the reduction in moderate-intensity O2 in the present study, 
there are other potential benefits of the systemic rise in plasma [NO2-] resulting from the 
ingestion of an acute bolus of NO3-. Recent evidence suggests that NO3- ingestion significantly 
improves the perfusion and oxygenation of skeletal muscle, particularly type II muscle fibers, 
during exercise [30,34]. The vascular effects of NO3- consumption are believed to be mediated 
acutely by NO2- or its reduction to the potent vasodilator NO [35,36]. Indeed, an increase in 
blood flow to exercising forearm muscle has been reported following acute NO2- infusion [37]. 
Moreover, the acute increase in plasma [NO2-] following acute NO3- ingestion has been closely 
coupled to a reduction in blood pressure, with both returning back to pre-treatment baseline 
values simultaneously at 24 h [6,20]. Collectively, these results suggest that improvements in 
perfusion and oxygenation following NO3- intake would not be preserved once NO3- 
supplementation is ceased and plasma [NO2-] returns back to baseline.  If this is the case, an 
acute dose of dietary NO3- following chronic supplementation may be beneficial before 
exercise in which improved oxygenation and perfusion in type II muscle fibers may be 
advantageous, i.e. high-intensity continuous and intermittent exercise. However, it must be 
acknowledged that a preserved improvement in vascular function could be possible if chronic 
NO3- supplementation results in a greater storage of tissue NO2- (as discussed above) and this 
tissue NO2- is released into the circulation during exercise [32]. Therefore, further research is 
required to determine if any improvement in high-intensity exercise performance following 
chronic NO3- supplementation is preserved after supplementation is stopped and plasma [NO2-
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] returns to baseline. In the present study, we focused on the effects of NO3- on submaximal 
exercise O2 and did not address possible changes in exercise performance.  
 
In conclusion, low dose (3 mmol) NO3- supplementation does not significantly reduce the O2 
cost of submaximal cycle exercise acutely, or when the supplementation period is extended to 
~4 weeks, despite a significant elevation in plasma [NO3-] and [NO2-] throughout the 
supplementation period. In contrast, the greater elevation in plasma [NO3-] and [NO2-] 
following 6 mmol NO3- supplementation was accompanied by a reduction in the O2 cost of 
submaximal cycle exercise after 2 h (P = 0.06), 7 days and ~4 weeks (both P < 0.05) of 
supplementation. The present study also demonstrated that the reduction in submaximal 
exercise O2 after ~4 weeks supplementation with 6 mmol NO3- is preserved up to 24 h after 
the latest dose of NO3- is ingested and thus, in the absence of elevated plasma [NO2-]. To our 
knowledge, this study is the first to dissociate the reduction in submaximal exercise O2 from 
an increase in plasma  [NO2-] following NO3- supplementation. This novel observation implies 
that beneficial structural skeletal muscle adaptations had occurred and were preserved, and/or 
muscle [NO2-] remained elevated following chronic NO3- supplementation.  
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Figure Legends 
 
Fig. 1. Schematic illustration of the study design. Following pre-treatment tests, all subjects 
were allocated to receive 6 mmol NO3-, 3 mmol NO3- or placebo for 28 – 30 days. All subjects 
completed two moderate-intensity bouts of cycle, 2 h post-ingestion (day 1; acute), and after 
7, 28 and 30 days of supplementation. In the 3 mmol and 6 mmol NO3- groups, subjects were 
randomised to receive a dose of placebo or NO3- 2 h prior to exercise testing in a 
counterbalanced order on days 28 and 30 of supplementation. This design enabled the efficacy 
of chronic NO3- supplementation in the absence and presence of an acute NO3- dose on the day 
of exercise testing to be determined. See main text for more details.  
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 Fig. 2. Change (∆) relative to pre-treatment baseline in plasma [NO3-] (panel A) and [NO2-] 
(panel B) following acute (2 h), 7 d and 28-30 d (CHR + ACU) supplementation with 6 mmol 
NO3- (squares), 3 mmol NO3- (triangles) and placebo (circles). Values are mean ± SE. * 
significant difference from pre-treatment baseline (P < 0.05); # significant difference from 
placebo group (P < 0.05); ¥ significant difference from placebo and 3 mmol NO3- group (P < 
0.05)  
  
Fig. 3. Change (∆) relative to pre-treatment baseline in plasma [NO3-] (panel A) and [NO2-] 
(panel B) following 28 – 30 d supplementation with 6 mmol NO3- (squares) and 3 mmol NO3- 
(triangles) when subjects consumed an acute dose of NO3- (CHR + ACU) or placebo (CHR) 2 
h prior to assessment. Values are mean ± SE. * significant difference from pre-treatment 
baseline (P < 0.05).  
 
Fig. 4. The effect of NO3- supplementation on end-exercise O2 during moderate-intensity 
cycle. Panel A: Change (∆) relative to pre-treatment baseline in end-exercise O2 following 
acute (2 h), 7 d and 28-30 d (chronic + acute) supplementation with 6 mmol NO3- (squares), 3 
mmol NO3- (triangles) and placebo (circles). Panel B: Change (∆) relative to pre-treatment 
baseline in end-exercise O2 following 28 – 30-days supplementation with 6 mmol NO3- 
(squares) and 3 mmol NO3- (triangles) when subjects consumed a dose of NO3- (CHR + ACU) 
or placebo (CHR) 2 h prior to assessment. Values are mean ± SE. O2, oxygen uptake. * 
Significant difference from pre-treatment baseline (P < 0.05); ₮ trend towards difference from 
pre-treatment baseline (P < 0.10); # significant difference from placebo group (P <  
0.05); ¥ trend towards difference from placebo group (P < 0.10).  
 
Table 1. Subject characteristics. Data expressed as mean ± SD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 PLA 3 mmol NO3- 6 mmol NO3- 
    
 n 11 (7 male) 11 (6 male) 12 (6 male) 
Age (yr) 21 ± 4 21 ± 2 22 ± 3 
Weight (kg) 75.9 ± 20.4 74.4 ± 9.8 70.5 ± 10.4 
Height (m) 1.74 ± 0.11 1.73 ± 0.08 1.75 ± 0.09 
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